Pinebridge Investments L.P. Has $1.76 Million Holdings in Haemonetics Co. (NYSE:HAE)

Pinebridge Investments L.P. boosted its holdings in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 42.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,483 shares of the medical instruments supplier's stock after buying an additional 6,727 shares during the period. Pinebridge Investments L.P.'s holdings in Haemonetics were worth $1,755,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. TD Waterhouse Canada Inc. acquired a new stake in shares of Haemonetics during the 4th quarter valued at about $25,000. Covestor Ltd boosted its holdings in Haemonetics by 146.8% during the fourth quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock valued at $58,000 after purchasing an additional 439 shares in the last quarter. Whittier Trust Co. bought a new stake in shares of Haemonetics in the 4th quarter valued at approximately $62,000. Parkside Financial Bank & Trust raised its holdings in shares of Haemonetics by 25.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after buying an additional 240 shares in the last quarter. Finally, AlphaQuest LLC lifted its position in shares of Haemonetics by 36,520.0% during the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock worth $143,000 after buying an additional 1,826 shares during the period. Institutional investors own 99.67% of the company's stock.

Analyst Ratings Changes

HAE has been the topic of a number of analyst reports. StockNews.com cut Haemonetics from a "buy" rating to a "hold" rating in a research report on Saturday, February 15th. Bank of America downgraded shares of Haemonetics from a "neutral" rating to an "underperform" rating and cut their price target for the company from $95.00 to $68.00 in a report on Friday, February 7th. Needham & Company LLC reduced their price target on shares of Haemonetics from $108.00 to $104.00 and set a "buy" rating on the stock in a research report on Tuesday, March 18th. Raymond James reaffirmed a "strong-buy" rating and set a $115.00 price objective (down previously from $120.00) on shares of Haemonetics in a report on Friday, February 7th. Finally, JMP Securities reduced their target price on Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a report on Friday, February 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Haemonetics has an average rating of "Moderate Buy" and an average price target of $101.22.

Haemonetics Trading Up 1.5 %

NYSE:HAE traded up $0.95 during trading hours on Friday, hitting $63.94. 534,756 shares of the stock were exchanged, compared to its average volume of 691,967. The company's 50 day moving average is $62.73 and its two-hundred day moving average is $71.72. The company has a market capitalization of $3.21 billion, a P/E ratio of 25.17, a price-to-earnings-growth ratio of 1.11 and a beta of 0.41. Haemonetics Co. has a twelve month low of $55.30 and a twelve month high of $97.97. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. On average, sell-side analysts anticipate that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.